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Immune checkpoint inhibitors (ICI) have become the standard of care treatment for
several tumor types. ICI-induced pneumonitis is a serious complication seen with
treatment with these agents. Cancer has been reported to be one of the risk factors
for severe coronavirus disease 2019 (COVID-19) caused by infection with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), that has engulfed the world in the
last couple of months. In patients with cancer treated with ICI who present at the
emergency department with respiratory symptoms during the COVID-19 pandemic,
correct diagnosis can be challenging. Symptoms and radiological features of ICI
pneumonitis can be overlapping with those of COVID-19 related pneumonia. For the
latter, dexamethasone and remdesivir have shown encouraging results, while vaccines
are currently being evaluated in phase III trials. The mainstay of treatment in ICI
pneumonitis is immunosuppressive therapy, as this is a potentially fatal adverse event.
It has been speculated that immunosuppression may be associated with increased
risk of progression to severe COVID-19, especially during the early stage of infection
with SARS-CoV-2. Therefore, distinction between these two entities is warranted. We
summarize the clinical, radiological features as well as additional investigations of both
entities, and suggest a diagnostic algorithm for distinction between the two. This
algorithm may be a supportive tool for clinicians to diagnose the underlying cause of
the pneumonitis in patients treated with ICI during this COVID-19 pandemic.
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INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus
disease 2019 (COVID-19) pandemic that has infected 10 million people and caused half a million
deaths as of June 30th, 2020 (1). Symptoms of COVID-19 can be similar to a common cold
such as fever, coughing and shortness of breath. However, some patients experience a severe
pneumonia, with acute respiratory distress syndrome (ARDS) and sometimes multi-organ failure.
The in-hospital mortality is reported to be up to 25% (2). This is in contrast to the case fatality
rate of COVID-19 in general, which was initially thought to be 15%, but in countries with rigorous
testing appeared to be much lower at 0.3% (3).
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Comorbidities were found in 77% of patients who died of
severe COVID-19, with the majority being cardiopulmonary,
liver or kidney disease, obesity, dementia, but also malignancy
(2). Other factors associated with severe COVID-19 resulting in
in-hospital mortality are increasing age and male sex. Cancer
itself is a risk factor for infection with SARS-CoV-2, as patients
with cancer commonly have an immunosuppressive status due
to the cancer itself or due to the anticancer treatment (4).
After adjusting for comorbidity, this risk of a severe outcome
with COVID-19 seems to be higher for cancer patients. The
highest risk of severe COVID-19 in cancer patients is seen in
patients with lung or hematological cancer (5). In addition,
patients with metastatic disease have a higher risk of severe
outcome than patients with early stage disease. In the latter
group, the outcome seems to be similar to non-cancer patients.
Data regarding the impact of the specific anticancer therapy on
the COVID-19 course was initially sparse. Recently, more insight
was provided and anticancer therapy does not seem to influence
the outcome of COVID-19 patients (6). Importantly, immune
checkpoint inhibitors (ICI), standard of care treatment for several
tumor types, do not appear to impact the severity of COVID-
19 (7). However, one of the adverse events of ICI is ICI-induced
pneumonitis and the clinical symptoms as well as the radiological
findings can be overlapping with COVID-19 related pneumonia.
It can be a challenge to distinguish between ICI pneumonitis
or COVID-19 pneumonia. ICI-induced pneumonitis is
treated with systemic steroids and if necessary additional
immunosuppressive drugs. Recently, the RECOVERY trial has
shown that systemic corticosteroids reduce mortality in patients
with COVID-19 needing invasive ventilation or supplemental
oxygen therapy, but not in patient that do not require respiratory
support. In addition, recently a short course of low dose
corticosteroids proved to be safe in patients with non-severe
COVID-19 (8). We should note, however, that while treatment
with steroids may be reasonably safe based upon these reports,
treatment with systemic steroids in the replication phase of
respiratory viral infections was shown to be detrimental in the
case of influenza virus (9). Discriminating between these two
etiologies is of utmost importance to prevent patients being
treated incorrectly, with an increased risk of either a severe
course of ICI-induced pneumonitis or COVID-19 pneumonia.
Here, we will discuss the pathophysiology, clinical symptoms,
radiological features as well as additional investigations for both
diseases. Lastly, we will discuss possible ways to help the clinician
in establishing the correct diagnosis.
ICI PNEUMONITIS
ICI-pneumonitis is defined as the development of dyspnea
and/or other respiratory signs/symptoms in the presence of new
infiltrates on chest imaging and in the absence of new respiratory
infection (based on microbiology evaluation of either sputum of
BAL fluid) in patients being treated with ICI (10). ICI-therapy
derives its anti-tumor effect by blocking inhibitory pathways in
the anti-tumor immune response. Blockade of the programmed
death-1/programmed death-ligand 1(PD-1/PD-L1) pathway is a
frequently used treatment in several malignancies. It can lead
to a decrease in immune self-tolerance, which in turn may lead
to a plethora of side effects in the form of inflammation of the
organ(s) in question (11–13), one of which is pneumonitis (10).
The reported incidence for ICI pneumonitis is around 1–
7% with higher incidences reported in patients treated with
combination therapy (14, 15). However, outside of clinical trials
the reported incidence appears strikingly higher and is up to
19% (15). The incidence of pneumonitis may also be related to
tumor type as it seems to be higher in patients with non-small cell
lung cancer than in patients with melanoma (16). The mortality
rate of ICI-pneumonitis is higher compared with immune related
adverse events associated with other organs and can approach
25% in some studies (16, 17).
Clinical Manifestation
The most common symptoms of ICI pneumonitis are dyspnea
and coughing. Chest pain can also occur, and sometimes patients
present with fever and infectious causes need to be excluded (16).
Physical examination can be normal, although in some patient
Velcro crackles can be heard in the lungs. ICI pneumonitis can
start from initiation of ICI therapy (18) and can even occur
after discontinuarion of ICI treatment (19) with a median time
to onset of 2.8 months (20). The onset can be acute, subacute
or chronic. While some patients with ICI pneumonitis do not
experience any symptoms (16), in some patients presenting with
the most severe form of ICI pneumonitis, tachypnea, severe
hypoxemia, and widespread alveolar infiltrates are often seen.
This severe clinical entity is similar to the acute respiratory
distress syndrome (ARDS).
Laboratory Examination
In laboratory examination, routine blood tests may show elevated
white blood cells and/or neutrophils, but normal blood counts
can be present as well. Erythrocyte sedimentation and C-reactive
protein are often elevated (16).
Bronchoscopy
In ICI pneumonitis, bronchoscopy is mainly used to exclude
infectious pneumonia. Using bronchoscopy, a deep sputum
sample can be collected, which is reliable for elimination of
the differential diagnosis of infection and guidance of anti-
microbial therapy (21). In ICI pneumonitis, BAL fluid often
show lymphocytic inflammation of alveoli with an increased
proportion of lymphocytes in the cell count [normal lymphocyte
count≈11%, in ICI pneumonitis≈37% (22, 23)]. Transbronchial
biopsies during bronchoscopy can be considered and may be
helpful to make the diagnosis (24).
Imaging
The imaging modality of choice is high resolution computed
tomography (HRCT). A wide spectrum of imaging
manifestations in ICI–related pneumonitis has been reported
including ground glass areas, consolidations, septal thickening,
traction bronchiectasis and features of acute interstitial
pneumonitis (AIP), such as consolidations and volume loss,
dependent on severity of toxicity (20). Areas of ground glass and
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consolidation are most commonly reported, noted in 70–80% of
cases (15), while septal thickening and traction bronchiectasis
are only noted in 15–20% of cases.
Manifestations of ICI-pneumonitis aremostlymultifocal, with
peripheral involvement as the second most common; the lower
lobes are most frequently involved (25). These manifestations
mainly show patterns of interstitial lung diseases (Figures 1A,B).
The most commonly observed ICI pattern is organizing
pneumonia (OP), present in 65% of ICI pneumonitis (10),
showing bilateral patchy opacities with a peripheral or
peribronchovascular predominance mainly located in the
middle and lower parts of the lungs (24, 26). These opacities
can be combined with ground glass opacities (GGO) and
pulmonary nodules can also be seen (27). The second most
described pattern in ICI-therapy is the non-specific interstitial
pneumonia (NSIP) pattern, which is found in 15% of ICI
pneumonitis (10, 24). NSIP shows GGOs and subpleural
reticulation with a lower zone predominance and usually a fairly
symmetric presentation. Hypersensitivity pneumonitis (HP) is
a less common manifestation accounting for 10% of the ICI
pneumonitis presenting with ill-defined centrilobular nodules,
similar to the nodules seen in HP due to other triggers (10). The
most severe form of ICI-pneumonitis is the AIP, occurring in
10% of ICI pneumonitis (28). AIP presents with diffuse GGO or
consolidative opacities involving the majority and sometimes the
entirety of the lungs. In addition, interlobular septal thickening
and “crazy-paving” patterns (i.e., combination of GGO and
reticulation) can be seen (27). Of note, these different patterns of
ICI-related pneumonitis can coexist in the same patient, either
simultaneously or successively in case of rechallenge with ICIs.
Pathology
As in radiologic assessment, four accompanying key patterns of
ICI pneumonitis can be recognized on pathologic examination;
OP, NSIP, HP, and diffuse alveolar damage (DAD) (21).
OP affects distal bronchioles, respiratory bronchioles, alveolar
ducts, and alveolar walls and is typically characterized by
excessive proliferation of granulation tissue plugs in the distal
airspaces with infiltration by plasma cells and lymphocytes
(29). In NSIP, the findings on histological samples are fibrosis
with inflammatory cell infiltration which is diffuse combined
with uniform and diffuse thickening of alveolar walls (30).
Histopathological examination of HP usually is characterized
by poorly formed non-caseating granulomas (31). DAD is the
histopathologic entity which is found in patients with AIP and
is characterized by widespread injury of the alveoli that results in
substantial capillary leak and non-cardiogenic pulmonary edema.
Histopathologic appearance of DAD is similar to that of ARDS
and is characterized by the thickening of the alveolar membranes,
hyaline membrane deposition in addition to infiltration with
inflammatory cells (28).
COVID-19
SARS-CoV-2 is caused by an recently emerged RNA coronavirus
related to SARS-CoV and Middle East respiratory syndrome
coronavirus (MERS-CoV). Symptoms of SARS-CoV-2 infection
are also similar to the other coronaviruses (32). Although cases
have been described at all ages, the virus is more likely to lead
to severe interstitial pneumonia in high-risk individuals, such as
the elderly and those with comorbidities such as cancer. This
can in turn lead to ARDS and multiorgan failure, which can
prove to be fatal. Affected individuals can present themselves
with different clinical symptoms, biochemical abnormalities and
radiological findings (33, 34). In contrast to the seasonal flu,
bacterial superinfection does not seem to play a major role in the
fatality associated with SARS-COV-2.
Clinical Manifestation
The clinical manifestation of COVID-19 can range from mild
to severe (35). The most reported symptoms are fever, cough,
dyspnea, myalgia or fatigue. Less commonly reported symptoms
include headache, loss of smell and taste, abdominal pain,
diarrhea, runny nose, and productive cough (35).
Virology
Reverse transcriptase polymerase chain reaction (RT-PCR) can
be performed on nasopharyngeal swabs, tracheal aspirate or BAL
specimens. BAL specimens give the highest positive rates (93%),
followed by sputum (72%), nasal swabs (63%), bronchoscopic
brush (46%), and phanyngeal swabs (32%) (36). A negative test,
therefore, does not exclude SARS-CoV-2 infection, especially in
highly exposed persons and at the beginning of the infection. If
only a swab was performed, it may be advisable to repeat the test
or to collect a deeper respiratory tract sample, such as tracheal
aspirate or BAL. Nevertheless, as the RT-PCR of SARS-CoV-2
RNA has a high specificity, but a limited sensitivity of around
77% (37), biochemical and radiological features might be useful
in diagnosing COVID-19, especially in clinically highly suspect
cases with initial negative PCR results (38) and for triage while
awaiting RT-PCR results.
Laboratory Examination
Laboratory examination shows significantly reduced lymphocyte
counts in majority of patients and is correlated with
the severity of disease (39). In addition, prolongation of
prothrombin times (PT) and elevation of fibrinogen degradation
products (FDPs) and D-dimers have been described. Soluble
interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) were
significantly increased in patients with severe COVID-19. In
all these measurements, critically ill patients had significantly
higher/lower values (depending on tested laboratory parameter)
than less severe cases (40). Serum ferritin levels are also elevated
in severe cases of SARS-CoV-2 infection (40–42). Overall,
laboratory examination can aid in establishing the diagnosis,
but none of the blood tests are sensitive or specific to make the
diagnosis of acute SARS-CoV-2 infection by themselves.
Bronchoscopy
Little is known about the bronchoscopic findings in patients with
COVID-19; as bronchoscopy is associated with an increased risk
of infection with SARS-CoV-2 for the health care personnel,
and is therefore not frequently performed. The (inter)national
guidelines state the following (43): Bronchoscopy (flexible and
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FIGURE 1 | (A,B) A patient with ICI pneumonitis. Although ground glass opacities are present (A), consolidations outside the areas of ground glass opacities are the
dominant feature (B), corresponding to a pattern of organizing pneumonia. (C,D) Two cases of RT-PCR proven COVID-19. One patient with typical well-demarcated
slightly rounded subpleural ground glass opacities with thickened inter- and intralobular septa within this area (crazy paving): CO-RADS 5 (C). The second patient
shows well-demarcated, but not rounded, bilateral subpleural ground glass opacities with early thickening inter- and intralobular septa (D). During the COVID-19
pandemic this case was judged as very highly suspicious (CO-RADS 5), but this case lacks confirmatory features.
rigid) for urgent or emergent reasons should be considered
only if a lifesaving bronchoscopic intervention is deemed
necessary. Indications include massive hemoptysis, benign or
malignant severe airway stenosis, or suspicion of an alternative
or secondary infectious etiology or malignant condition with
resultant significant endobronchial obstruction. However, when
caring for patients where the initial evaluations are not
conclusive in making the distinction between COVID-19 and
ICI-pneumonitis, bronchoscopy may prove to be useful to collect
specimens needed to test SARS-CoV-2 via RT-PCR, given the
higher positive rate of BAL when compared to nasopharyngeal
swab. Of note, bronchoscopy must be performed while taking
maximal precautions including personal protective equipment.
Imaging
Early reports from Wuhan, China, described typical CT features
seen in COVID-19 pneumonia and since the spread of the disease
over Europe and other parts of the world, many publications
from different countries have described the typical features seen
on imaging (44–48).
Typical CT features of COVID-19 include bilateral subpleural
areas of GGOs, mainly in the lower lung zones and are often
extensive (Figures 1C,D). Features have been described to be
dependent on disease duration with development of thickened
intralobular septa in the areas of GGOs after 8–10 days of disease
resulting in a crazy paving pattern. In those cases that progress
to severe disease, areas of consolidation can develop, both in
the pre-existent GGO areas but also in lung areas that were
previously not involved. In the healing stage of disease features
of organizing pneumonia are seen.
Although the typical hallmarks of COVID-19 related
pneumonia on CT imaging are very rarely seen in other diseases,
not all patients with COVID-19 present with these typical
features. It has been described that about half of the patient
population has a normal CT scan up to 48 h after start of
symptoms (49). Early publications reported an extremely high
Frontiers in Oncology | www.frontiersin.org 4 October 2020 | Volume 10 | Article 577696
Dumoulin et al. COVID-19 or ICI Pneumonitis?
FIGURE 2 | Diagnostic algorithm for discrimination between COVID-19 and ICI pneumonitis. CRP, C-reactive protein; ERS, erythrocyte sedimentation rate; PT,
prothrombin time; S-IL-2-R, soluble interleukin 2 receptor; IL-6, interleukin 6; BAL, bronchoalveolar lavage; GGO, ground-glass opacity; OP, organizing pneumonia;
NSIP, non-specific interstitial pneumonia; HP, hypersensitivity pneumonitis. For features of OP, NSIP, and HP we refer to the accompanying text.
sensitivity (up to 97%) for CT scanning in diagnosing COVID-
19 (50), but with a low specificity of only 37%. Therefore,
several standard reporting schemes were developed to improve
communication about level of suspicion based on imaging
features (51, 52). In the Netherlands, the COVID-19 reporting
and data system (CO-RADS) was developed and used to grade
the level of suspicion on COVID-19 based on CT features in
patients with moderate to severe symptoms with good accuracy
in predicting COVID-19 (52). This reporting system ranges from
CO-RADS 0 (not interpretable) to CO-RADS 6 (RT-PCR proven
SARS-CoV2) (52), for radiologists, the most relevant ranges are
from CO-RADS 1 (no signs of infectious disease) to CO-RADS
5 (very high likelihood of COVID-19), with CO-RADS 3 being
equivocal. CO-RADS 3 can represent early cases of COVID-19
with an unifocal ground glass opacity, but also cases with ground
glass without the typical subpleural (including the mediastinal
pleura and the fissures) location and less well-demarcated or
diffuse ground glass, often noted in other viral pneumonias, but
also seen in heart failure, drug induced pulmonary disease and
focal fibrosis. NSIP pattern can be seen in healing disease, but is
rare in the acute phase.
Several studies have reported on the high incidence of
pulmonary emboli in patients with COVID-19 (53, 54).
Therefore, it has been proposed to add pulmonary CTA in the
diagnostic pathway for COVID-19 (55).
Pathology
COVID-19 related ARDS causes pathological changes of DAD
in the lungs. Recently, the longer term outcomes of ARDS have
reported lung fibrosis as a possible outcome of COVID-19 ARDS
(56). Fibrous lesions in fact may form during the healing of
pulmonary chronic inflammation or proliferative diseases, with
scar tissue gradually replacing cellular components (56).
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Soon after the COVID-19 outbreak, multiple papers reported
autopsy findings of pulmonary embolisms (57, 58). Coagulation
dysfunction appears to be common in COVID-19, with the
lungs from patients with COVID-19 showing distinctive
vascular features, consisting of severe endothelial injury
associated with the presence of intracellular virus and disrupted
cell membranes. Histologic analysis of pulmonary vessels
in patients with COVID-19 showed widespread thrombosis
with microangiopathy (59). In a study with 184 patients with
COVID-19 admitted to ICU, a 31% incidence of thrombotic
complications was shown reinforcing the recommendation
to strictly apply pharmacological thrombosis prophylaxis in
all patients with COVID-19 admitted to the ICU (53). In
addition, pulmonary embolisms should always be considered
as a differential diagnosis, for which therapy guidelines are in
place (60).
DISCUSSION
For patients with cancer receiving immunotherapy that have
symptoms like dyspnea, fever and/or coughing, distinguishing
between ICI pneumonitis or COVID-19 is challenging. However,
discrimination between these two entities is essential to provide
optimal care to the patient.
Misdiagnosis of COVID-19with ICI pneumonitis can result in
corticosteroid administration during the replication phase of the
virus, the outcomes of which are currently unknown. In addition,
treating a patient incorrectly for ICI pneumonitis instead
of diagnosing COVID-19 could have negative consequences
for the cancer treatment. On the other hand, not timely
treating ICI pneumonitis can result in irreversible lung injury
with a fulminant clinical course. Therefore, recognizing ICI
pneumonitis is crucial, given the high mortality associated with
this clinical entity.
Since clinical presentation of ICI pneumonitis and COVID-
19 are similar and RT-PCR results can take up to 24 h and can
be false negative, diagnostic tools such as lab results and imaging
can be helpful for discrimination between both entities.
With regard to imaging, ICI pneumonitis and COVID-19
show overlapping features and discrimination on HRCT can
be difficult. Both entities can show patchy GGOs and areas of
consolidation, often with a fairly symmetrical distribution and
a lower lobe and peripheral predominance. Several reporting
systems have been developed to rate the level of suspicion on
COVID-19 based on well-described features with CO-RADS
being reported to have good interobserver agreement (52) in
contrast to the reporting system proposed by the RSNA (61).
These features include GGO areas with or without areas of
consolidation, in lung regions close to the visceral pleural
surfaces with a multifocal, bilateral distribution. Crazy paving
pattern, rounded shape of the GGO areas and vessel dilatation are
confirmatory features. CO-RADS categories 4–5 display a high to
remarkably high likelihood of COVID-19 in a high prevalence
situation with good to excellent accuracy (52). Not all cases
of COVID-19 present with typical features and some patients
show ground glass opacities without the typical distribution
and without confirmatory features, fulfilling the criteria for CO-
RADS 3 (i.e., equivocal). In this category an alternative cause of
symptoms including severe dyspnea is often likely.
The hallmarks of ICI pneumonitis overlap with features
of COVID-19. However, while a peripheral distribution is
common in both entities, COVID-19 is also frequently located
along the mediastinal pleural surfaces and the fissures. Crazy
paving is frequently seen in COVID-10 patients who have
symptoms for more than a week, while reticulation in ICI-
pneumonitis is often seen concomitant with areas of ground
glass, but not within the ground glass opacifications. Features
of organizing pneumonia are common in ICI pneumonitis,
but also seen in COVID-19. However, in COVID-19 these
features are rarely seen as the main feature in contrast to
cases of ICI pneumonitis. Furthermore, GGO is the major
feature in early COVID-19, while features of organizing
pneumonia are seen later in the course of disease. NSIP
pattern is often seen in ICI pneumonitis, but rare in cases of
acute COVID-19.
While both ICI pneumonitis and COVID-19 have typical
features which makes the alternative diagnosis less likely, not
all patients present with typical manifestations. In these cases,
imaging is not able to discriminate between both entities.
Fortunately, the number of CO-RADS 3 cases during the peak
of the COVID-19 pandemic was low (52).
Given the mediocre sensitivity of the RT-PCR, we
propose a diagnostic algorithm in order to assist clinicians
to discriminate between COVID-19 and ICI pneumonitis based
on laboratory, radiographical and pathological parameters,
as described in Figure 2. First step is RT-PCR, which can
confirm the diagnosis of COVID-19. However, due to the
possibility of a false negative RT-PCR result, COVID-19 is
not completely ruled out as a possible diagnosis. In those
cases, laboratory examination and imaging features can
be helpful in selecting patients who are still likely to have
COVID-19 despite the negative RT-PCR. In addition, they
may aid in determining the probability of ICI pneumonitis
and may suggest need to perform further workup such
as bronchoscopy. When the correct diagnosis has been
made, the underlying cause should be managed. While ICI
pneumonitis usually responds to treatment with corticosteroids,
some patients are refractory to this treatment. Moreover,
there may be suspicion for concurrent COVID-19 and ICI
pneumonitis in some patients, despite following the suggested
algorithm. In these patients, corticosteroids should be used
with precaution.
CONCLUSION
Discriminating between COVID-19 and ICI pneumonitis can be
a challenging task for clinicians with any level of experience.
The sensitivity of RT-PCR is low, and the consequences
of wrong interpretation can be too severe, to fully trust a
negative result in clinically suspicious cases. Therefore, additional
parameters must be considered when assessing patients treated
with ICI and a suspicion of COVID-19. Based on imaging,
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lab values, RT-PCR and if necessary bronchoscopy with BAL,
we propose an algorithm to aid clinicians in daily practice
to establish the right diagnosis leading to the initiation of
correct treatment.
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